El año pasado, Anika Therapeutics Inc generó 64.41M USD en su segmento con mejor rendimiento, OEM Channel. United States realizó la mayor aportación, representando 70.06M USD el año pasado. Para el último trimestre, Anika Therapeutics Inc reportó unos ingresos de 18.70M USD para el periodo finalizado el 2026-06-30, procedentes del segmento con mejor rendimiento, OEM Channel. United States aportó los mayores ingresos, alcanzando los 19.80M USD.

Por negocio

Ingresos operativos

Proporción

Anual

Anual

Trimestral

OEM Channel

Commercial Channel

Joint Pain Management

Orthopedic Joint Preservation and Restoration

Non-Orthopedic

Orthobiologics

Surgical

Dermal

Licensing, milestone and contract revenue

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

OEM Channel

64.41M(57.09%)

77.77M(64.86%)

--(--)

Commercial Channel

48.41M(42.91%)

42.14M(35.14%)

--(--)

Joint Pain Management

--(--)

101.93M(61.16%)

97.89M(62.65%)

89.50M(60.56%)

83.03M(63.64%)

--(--)

Orthopedic Joint Preservation and Restoration

--(--)

54.88M(32.93%)

50.40M(32.26%)

48.59M(32.88%)

39.37M(30.18%)

--(--)

Non-Orthopedic

--(--)

9.86M(5.91%)

7.95M(5.09%)

9.70M(6.57%)

8.06M(6.18%)

6.08M(5.31%)

6.07M(5.75%)

Orthobiologics

--(--)

101.00M(88.13%)

93.56M(88.65%)

Surgical

--(--)

5.18M(4.52%)

5.51M(5.23%)

Dermal

--(--)

2.24M(1.96%)

396.00K(0.38%)

Licensing, milestone and contract revenue

--(--)

98.00K(0.09%)

--(--)

Por región

Ingresos operativos

Proporción

Anual

Anual

Trimestral

United States

Europe

Other

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

United States

70.06M(62.10%)

82.45M(68.76%)

86.91M(71.95%)

119.15M(76.26%)

113.83M(77.02%)

103.18M(79.09%)

90.30M(78.79%)

85.35M(80.86%)

Europe

22.21M(19.69%)

19.40M(16.18%)

17.31M(14.33%)

20.64M(13.21%)

19.58M(13.25%)

14.18M(10.87%)

14.74M(12.86%)

11.73M(11.11%)

Other

20.55M(18.21%)

18.06M(15.06%)

16.57M(13.72%)

16.45M(10.53%)

14.38M(9.73%)

13.10M(10.04%)

9.56M(8.34%)

8.47M(8.03%)